1. BY:
JAY PAL SINGH CHOUDHARY
ANUPMA TRIPATHI
SGSITS MBA
BIO-TECHNOLOGY PARKS
2. BIO-TECHNOLOGY
.Biotechnology or biotech is the use of living systems and organisms to
develop or make useful products, or "any technological application that
uses biological systems, living organisms or derivatives there of, to make
or modify products or processes for specific use UN Convention on
Biological Diversity .For thousands of years, humankind has used
biotechnology in agriculture, food production and medicine.
Biotechnology has applications in four major industrial areas, including
health care (medical), crop production and agriculture, non food
(industrial) uses of crops and other products.
(e.g. biodegradable plastics, vegetable oil, biofuels)
Biotechnology also draws on the pure biological sciences
(genetics, microbiology, animal cell culture, molecular
biology, biochemistry, embryology, cell biology)
3. BIO-TECHNOLOGY PARKS
BIO-TECHNOLOGY PARKS is that type of park in which we used
technological application that uses biological living systems and
organisms to develop or make useful products.
Biotech parks have been planned to provide financial and other logistical
support to new entrepreneurs having the intellectual capabilities to
develop new biotech products and processes.
Such entrepreneurs may find the parks attractive. Biotech Parks have
been created or planned/proposed in a number of states in India including
Tamil Nadu, Andhra Pradesh, Kerala, Karnataka, Uttar Pradesh, Punjab,
Maharashtra, Gujarat, Uttarakhand, Rajasthan, Delhi, Orissa, Madhya
Pradesh etc.
4. The Indian biotechnology sector is one of the fastest growing knowledge-
based sectors in India and is expected to play a key role in shaping
India's rapidly developing economy. With numerous comparative
advantages in terms of research and development (R&D) facilities,
knowledge, skills, and cost effectiveness, the biotechnology industry in
India has immense potential to emerge as a global key player.
Key role of the Biotech park:
- HEALTH CARE
- AGRICULTURE
- INDUSTRIAL APPLICATION
- ENERGY
Biotechnology Parks
5. Energy: Bio fuels, renewable energy sources have been identified
as thrust areas
Biotechnology Parks
Agriculture: Improvement in the quality and yield of crops, horticulture
and forest tree species, biopesticides and biofertilizers, processed food
and quality enhancers.
Health Care: Human and animal health care products including
therapeutic aids, immuno-diagnostics, biosensors, vaccines, gene
therapy, monoclonal antibodies, neutraceuticals and cosmetics
Industrial Application: Plants as bioreactors, enzymes, chemicals and
polymers
6. Timeline of Biotechnology
Pre-20th Century:
1663 First recorded description of living cells recorded by Robert.
1802 The first recorded use of the word biology.
1824 Henri discovers that tissues are composed of living cells.
20th Century:
1953 James and Francis describe the structure of DNA.
1974 Scientist invent the first biocement for industrial applications.
21st Century:
2007 The first Nanoradio is described by Alex.
2012 31 year-old Zac Vawter successfully uses a nervous
system controlled bionic leg to climb the Chicago Willis Tower
7. Our vision for Biotechnology research, development and
commercialisation, in the next 10 years would thus focus on :
• Basic Research in New Biology and Biotechnology
(a) Genomics
(b) Bioinformatics
(c) Basic biological phenomena with potential application
• Agriculture, Plant and Animal Biotechnology
• Environment and Biodiversity
• Medical Biotechnology
• Biofuels
• Bioprocesses, Product Development, and Bioinstrumentation
• Human Resource Development
• Creation and Strengthening of Infrastructure in Existing Institutions and
setting up new Institutions
• Biotechnology for Societal Development
• Biosafety, Ethical and Proprietary Issues
8. Agriculture, Plant and Animal Biotechnology
Crops
Major thrust on :
•Higher productivity
•Enhanced nutritional status
•Value addition to crops as therapeutics
Stability against stresses : Insect pests and diseases still continue to
cause heavy crop losses. Focussing on specific crops and problems,
transgenic and / or marker-assisted selection approaches shall be
developed and used to evolve stress-tolerant crop varieties.
.
10. A SWOT Analysis of Biotechnology in India gives us
the following results:
Strengths:
• Human Resources: Trained manpower and knowledge base.
• Academic Resources: Good network of research laboratories.
• Industry Base: Well developed base industries (for example.
pharmaceuticals,seeds).
• International Experts: Access to intellectual resources of NRI’s in this area.
• Clinical Capability: Extensive clinical trials and research access to vast and
diverse diseases in the huge population.
• Bio-diversity: India’s human gene pools and unique plant, animal and
microbial diversity offer an exciting opportunity for genomic research.
• Stem Cells Research: Several labs have commenced research in stem cells
and have valuable stem cell lines.
11. Opportunities:
• Large domestic market
• Large export potential
• Low cost research base for international companies compared with
other countries.
• Vast and diverse disease based patient populations provide unique
opportunities for clinical research and trials.
• Supportive Government policy on embryonic stem cells research
provides a useful opportunity for international companies to pursue
such research in India.
• Human bio-diversity provides unique research opportunity in genomics.
• Plant and microbial bio-diversity provides vast prospecting
opportunities for new drugs.
12. •Missing links between research and commercialization.
•Lack of venture capital.
•Relatively low R&D expenditure by industry.
•Image of Indian industry – doubts about ability of Indian products to
meet International standards of quality.
Danger of anti-biotech propaganda gaining ground.
Inadequate protection of Intellectual Property Rights (IPR), significant
improvement remains to be undertaken in the areas of implementation
and enforcement.
Threats
Weakness
13. Conclusion:
The Indian Biotechnology Industry is set for rapid growth fueled by the
growing market size and number of products as well as increased
investments. The emergence of Biotech parks and state of the art Bio-IT
parks will further boost this growth.
Additionally, Indian biotech companies are set to capture the emerging
biogenerics opportunity that would arise with nearly $10 billion worth
biotech drugs going off-patent in the next 5 years. Although the
implementation of TRIPS was expected to cause a setback in the growth
of this industry, Frost & Sullivan’s analysis shows that this is not quite the
case here
